BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11704788)

  • 1. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
    Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
    Bone Marrow Transplant; 2001 Oct; 28(7):657-64. PubMed ID: 11704788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.
    Nath CE; Earl JW; Pati N; Stephen K; Shaw PJ
    Br J Clin Pharmacol; 2008 Jul; 66(1):50-9. PubMed ID: 18341668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
    Carreras E; Cahn JY; Puozzo C; Kröger N; Sanz G; Buzyn A; Bacigalupo A; Vernant JP
    Anticancer Res; 2010 Jul; 30(7):2977-84. PubMed ID: 20683042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.
    Takamatsu Y; Sasaki N; Ogata K; Yukawa E; Jimi S; Hara S; Tamura K
    Cancer Chemother Pharmacol; 2010 May; 65(6):1203-7. PubMed ID: 20169347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
    van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
    Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
    Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
    Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
    de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
    Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
    Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
    Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
    Hassan M; Oberg G; Björkholm M; Wallin I; Lindgren M
    Cancer Chemother Pharmacol; 1993; 33(3):181-6. PubMed ID: 8269597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
    Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of liposomal busulphan in man.
    Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
    Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of apparent clearance of valproic acid in adult Saudi patients.
    Alqahtani S; Alandas N; Alsultan A
    Int J Clin Pharm; 2019 Aug; 41(4):1056-1061. PubMed ID: 31222537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
    Ruiz-Argüelles GJ; Gomez-Almaguer D; Steensma DP
    Am J Hematol; 2012 Sep; 87(9):941. PubMed ID: 22674687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.